Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2005; 93(01): 1-2
DOI: 10.1160/TH04-11-0746
DOI: 10.1160/TH04-11-0746
Editorial Focus
Inside the two way association between malignancy and alteration of haemostasis
Authors
Further Information
Publication History
Received
15 November 2004
Accepted after revision
18 November 2004
Publication Date:
14 December 2017 (online)
-
References
- 1 Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
- 2 Heit JA, Silverstein MD, Mohr DN. et al The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63.
- 3 Di Micco P, D’Uva M. To understand the two way clinical association between cancer and thrombophilia. Exp Oncol 2003; 25: 243-4.
- 4 Trousseau A. Phlegmasia alba dolens. In: Bailliere JB, Editor. Clinique Medicale de l’Hotel Dieu de Paris, 2 nd Ed. 1865; 3: 654-712.
- 5 Brenner B. Arterial thrombotic syndromes in cancer patients. Haemostasis 2001; 31 (Suppl. 01) 43-4.
- 6 Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001; 106: 6-12.
- 7 Levi M. Cancer and DIC. Haemostasis 2001; 31 (Suppl. 01) 47-8.
- 8 Di Micco P, Niglio A, De Renzo A. et al Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report. J Transl Med 2004; 2: 7.
- 9 Monreal M, Raventos A, Lerma R. et al Pulmonary embolism in patients with upper extremity DVT associated to venous central lines. A prospective study. Thromb Haemost 1994; 72: 548-50.
- 10 Leone G, Sica S, Chiusolo P. et al Blood cells diseases and thrombosis. Haematologica 2001; 86: 1236-44.
- 11 Mamby CC, Love RR, Feizy JM. Protein S and Protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res Treat 1994; 30: 311-4.
- 12 Verheul HMW, Panigrahy D, Yuan J. et al Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 1999; 79: 114-8.
- 13 Rodeghiero F, Elice F. Thalidomide and thrombosis. Pathophysiol Haemost Thromb 2003; 33 (Suppl. 01) 15-18.
- 14 Falanga A. Tumor cell prothrombotic properties. Haemostasis 2001; 31 (Suppl. 01) 1-4.
- 15 Harbeck N, Kates RE, Gauger K. et al Urokinasetype plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004; 91: 450-6.
- 16 Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91: 22-36.
- 17 Varner JA, Nakada MT, Jordan RE. et al Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoProTM). Angiogenesis 1999; 3: 53-60.
- 18 Verheul HM, Hoekman K, Luykx-de Bakker S. et al Platelets: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
- 19 Rhee JS, Black M, Schubert U. et al The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004; 92: 394-402.
- 20 Xu Y, Shen Z, Wiper DW. et al Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-23.
- 21 Sorensen HT, Mellemkjaer L, Olsen JH. et al Prognosis of cancers associated to venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
- 22 Sase T, Wada H, Yamaguchi M. et al Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 2005; 93: 156-62.
- 23 Perkins GD, McAuley DF, Davies S. et al Discrepancies between clinical and postmortem diagnoses in critically ill patients: an observational study. Critical Care 2003; 7: R129-R132.